The immunoreactivity to lysosomal enzyme GLB1 (beta galactosidase, hydrolyzes of terminal non-reducing beta-D-galactose residues in beta-D-galactosides) is increased in Type 1 diabetes in humans and rats36. Here, GLB1 is linked to type 1 diabetes mellitus.